PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16225760-0 2005 Effect of protein kinase C alpha, caspase-3, and survivin on apoptosis of oral cancer cells induced by staurosporine. Staurosporine 103-116 protein kinase C alpha Homo sapiens 10-32 16225760-1 2005 AIM: To elucidate inhibition of protein kinase C alpha (PKC alpha) activity by staurosporine on apoptosis of oral cancer cell line tongue squamous cell carcinoma (TSCCa) cells and to clarify the role of survivin and caspase-3 in mediating apoptosis. Staurosporine 79-92 protein kinase C alpha Homo sapiens 32-54 16225760-1 2005 AIM: To elucidate inhibition of protein kinase C alpha (PKC alpha) activity by staurosporine on apoptosis of oral cancer cell line tongue squamous cell carcinoma (TSCCa) cells and to clarify the role of survivin and caspase-3 in mediating apoptosis. Staurosporine 79-92 protein kinase C alpha Homo sapiens 56-65 16225760-7 2005 Marked cell accumulation in G2/M phase was observed after 100 nmol/L staurosporine exposure for 6 h and 12 h. In addition, the percentage of apoptosis increased in a time-dependent manner, from 2.9% in control cultures to approximately 27.4% at 100 nmol/L staurosporine treatment for 24 h. Staurosporine displayed difference in inhibitory efficacy between cytosolic and membrance-derived PKC alpha. Staurosporine 69-82 protein kinase C alpha Homo sapiens 388-397 16225760-8 2005 The content of PKCalpha in membrane versus cytosol decreased quickly, from 0.45 in ethanol-treated control cultures to 0.18 after staurosporine exposure for 24 h (P<0.01). Staurosporine 130-143 protein kinase C alpha Homo sapiens 15-23 16225760-11 2005 Inhibition of PKCalpha activity might be a potential mechanism for staurosporine to induce apoptosis in this cell line. Staurosporine 67-80 protein kinase C alpha Homo sapiens 14-22 16117614-7 2005 They also substantiated that PKCalpha is a part of the TPA-activated upstream signal pathway of NF-kappaB, since NF-kappaB activity was inhibited by staurosporine (a PKC inhibitor) and pyrrolidine dithiocarbamate (an NF-kappaB inhibitor) in a western blot analysis. Staurosporine 149-162 protein kinase C alpha Homo sapiens 29-37 16117614-7 2005 They also substantiated that PKCalpha is a part of the TPA-activated upstream signal pathway of NF-kappaB, since NF-kappaB activity was inhibited by staurosporine (a PKC inhibitor) and pyrrolidine dithiocarbamate (an NF-kappaB inhibitor) in a western blot analysis. Staurosporine 149-162 protein kinase C alpha Homo sapiens 29-32 14522134-10 2003 The non-selective PKC inhibitors, staurosporine and Ro31-8220, significantly reduced histamine-induced superoxide production. Staurosporine 34-47 protein kinase C alpha Homo sapiens 18-21 11997388-4 2002 Staurosporine attenuated the relocation of PKCalpha-GFP to the cytosol and caused a stepwise accumulation of PKCalpha-GFP at the plasma membrane during ATP stimulation. Staurosporine 0-13 protein kinase C alpha Homo sapiens 43-51 11997388-4 2002 Staurosporine attenuated the relocation of PKCalpha-GFP to the cytosol and caused a stepwise accumulation of PKCalpha-GFP at the plasma membrane during ATP stimulation. Staurosporine 0-13 protein kinase C alpha Homo sapiens 109-117 11997388-7 2002 The ionomycin-induced transient translocation of PKCalpha-GFP was prolonged by staurosporine, diacylglycerol, and phorbol myristate acetate. Staurosporine 79-92 protein kinase C alpha Homo sapiens 49-57 11997388-8 2002 Experiments using permeabilized cells showed that staurosporine or the elimination of ATP and Mg2+ decreases the rate of dissociation of PKCalpha-GFP from the membrane. Staurosporine 50-63 protein kinase C alpha Homo sapiens 137-145 12190943-9 2002 The effect of staurosporine could be explained by its paradoxical action (activation) on protein kinase C (PKC) in keratinocytes. Staurosporine 14-27 protein kinase C alpha Homo sapiens 107-110 12176659-7 2002 Staurosporine, an inhibitor of protein kinases C (PKC), inhibited the AT1 desensitisation. Staurosporine 0-13 protein kinase C alpha Homo sapiens 50-53 11483407-6 2001 PKC inhibitors (staurosporine, Ro 31-8220, calphostin C, or Go 6976) also inhibited TNF-alpha-induced response. Staurosporine 16-29 protein kinase C alpha Homo sapiens 0-3 12083800-8 2002 The CG exocytosis and PKC redistribution induced by PMA could be blocked by the PKC inhibitor staurosporine. Staurosporine 94-107 protein kinase C alpha Homo sapiens 22-25 12083800-8 2002 The CG exocytosis and PKC redistribution induced by PMA could be blocked by the PKC inhibitor staurosporine. Staurosporine 94-107 protein kinase C alpha Homo sapiens 80-83 11994256-9 2002 The effects of SIN-1 were blocked by the NO scavenger phenyl-tetramethyl-imidazoline-oxyl-oxide as well as by the PKC inhibitor staurosporine. Staurosporine 128-141 protein kinase C alpha Homo sapiens 114-117 11751911-5 2002 Protein kinase C (PKC) inhibitors (staurosporine or Ro 31-8220) also inhibited IFN-gamma-induced response. Staurosporine 35-48 protein kinase C alpha Homo sapiens 18-21 11158204-3 2001 However, we have recently found that high concentrations of staurosporine up to 1 microM: can only partially inhibit IL-3-stimulated Bcl2 phosphorylation but completely block PKCalpha-mediated Bcl2 phosphorylation in vitro, indicating the existence of a non-PKC, staurosporine-resistant Bcl2 kinase (SRK). Staurosporine 60-73 protein kinase C alpha Homo sapiens 175-183 11182772-9 2001 The inhibition of the Na+/K+ATPase activity was dependent on protein kinase C (PKC) activation since PKC antagonists (calphostin C and staurosporine) abolished the inhibitory effect of Ang II, and the PKC activator phorbol 12-myristate 13-acetate reduced transporter activity. Staurosporine 135-148 protein kinase C alpha Homo sapiens 79-82 11182772-9 2001 The inhibition of the Na+/K+ATPase activity was dependent on protein kinase C (PKC) activation since PKC antagonists (calphostin C and staurosporine) abolished the inhibitory effect of Ang II, and the PKC activator phorbol 12-myristate 13-acetate reduced transporter activity. Staurosporine 135-148 protein kinase C alpha Homo sapiens 101-104 11182772-9 2001 The inhibition of the Na+/K+ATPase activity was dependent on protein kinase C (PKC) activation since PKC antagonists (calphostin C and staurosporine) abolished the inhibitory effect of Ang II, and the PKC activator phorbol 12-myristate 13-acetate reduced transporter activity. Staurosporine 135-148 protein kinase C alpha Homo sapiens 101-104 11158204-3 2001 However, we have recently found that high concentrations of staurosporine up to 1 microM: can only partially inhibit IL-3-stimulated Bcl2 phosphorylation but completely block PKCalpha-mediated Bcl2 phosphorylation in vitro, indicating the existence of a non-PKC, staurosporine-resistant Bcl2 kinase (SRK). Staurosporine 60-73 protein kinase C alpha Homo sapiens 175-178 10523856-6 1999 TPA-mediated MDR1 induction was inhibited by several PKC inhibitors including staurosporine, H7 and calphostin C. Staurosporine 78-91 protein kinase C alpha Homo sapiens 53-56 10627456-8 2000 The PKC inhibitors staurosporine and calphostin C prevented EPO-induced erythroid differentiation. Staurosporine 19-32 protein kinase C alpha Homo sapiens 4-7 11093788-4 2000 PKC inhibitors (staurosporine, Ro 31-8220, calphostin C, or Go 6976) also inhibited IL-1beta-induced response. Staurosporine 16-29 protein kinase C alpha Homo sapiens 0-3 9593858-5 1998 A role for PKC in ET-1-induced AA release is supported by the findings that the phorbol ester, PDBu, increased AA release by 96%, that prolonged treatment of the cells with PDBu resulted in the selective down regulation of PKCalpha and the complete inhibition of ET-1-induced AA release, and that pretreatment of the cells with staurosporine or RO 31-8220, PKC inhibitors, blocked the ET-1-induced AA release. Staurosporine 328-341 protein kinase C alpha Homo sapiens 11-14 9593858-5 1998 A role for PKC in ET-1-induced AA release is supported by the findings that the phorbol ester, PDBu, increased AA release by 96%, that prolonged treatment of the cells with PDBu resulted in the selective down regulation of PKCalpha and the complete inhibition of ET-1-induced AA release, and that pretreatment of the cells with staurosporine or RO 31-8220, PKC inhibitors, blocked the ET-1-induced AA release. Staurosporine 328-341 protein kinase C alpha Homo sapiens 223-226 9346296-5 1997 GDP and its analogue, guanosine 5"-O-[beta-thio]diphosphate, inhibited the stimulatory effect of GTP[S], whereas the PMA response was prevented by the nonselective PKC inhibitor, staurosporine, but not vice versa. Staurosporine 179-192 protein kinase C alpha Homo sapiens 164-167 9734941-5 1998 The part played by protein kinase C (PKC) signalling was examined by down-regulation with phorbol ester and with the inhibitors Goe 6976 and staurosporine. Staurosporine 141-154 protein kinase C alpha Homo sapiens 37-40 9769475-3 1998 Treatment of cells with PKC inhibitors (staurosporine, bisindolylmaleimide, or G?6976) resulted in morphological alterations and reorganization of actin filaments similar to retinoic-acid-treated cells. Staurosporine 40-53 protein kinase C alpha Homo sapiens 24-27 9361188-8 1997 PKC inhibitors, calphostin C (10 nM), and staurosporine (5 nM), inhibited strain-induced PKC activation and keratinocyte proliferation, but did not block the effects of strain on cellular morphology or alignment. Staurosporine 42-55 protein kinase C alpha Homo sapiens 89-92 9392422-3 1997 The protein kinase C (PKC) inhibitors calphostin C and staurosporine prevented TPA-mediated LDL receptor mRNA induction. Staurosporine 55-68 protein kinase C alpha Homo sapiens 22-25 7710931-1 1995 Inhibitors of protein kinase C (PKC) such as the staurosporine analogues UCN-01 and CGP 41251 possess antineoplastic properties, but the mechanism of their cytostatic action is not understood. Staurosporine 49-62 protein kinase C alpha Homo sapiens 32-35 8943287-6 1996 In parental MCF-7 cells, PKC inhibitors (GF109203X (bisindolylmaleimide I) and staurosporine) reduced IRS-1 content. Staurosporine 79-92 protein kinase C alpha Homo sapiens 25-28 8617370-3 1996 PMA, a protein kinase C (PKC) activator, enhanced cAMP accumulation in 293AC-V cells dose-and time-dependently and this enhancement was abolished by staurosporine. Staurosporine 149-162 protein kinase C alpha Homo sapiens 25-28 8554927-9 1995 The latter effect was specific, since it was reversed by treatment with the PKC inhibitors staurosporine and chelerythrine. Staurosporine 91-104 protein kinase C alpha Homo sapiens 76-79 7547506-4 1995 Furthermore, PKC inhibitors, such as staurosporine or calphostin C, prevent TPA-induced differentiation but not cell growth arrest. Staurosporine 37-50 protein kinase C alpha Homo sapiens 13-16 9150270-5 1997 Staurosporine also increased membrane association of MARCKS in a PKC-independent manner, as no change in MARCKS phosphorylation was noted and bis-indolylmaleimide (a more specific PKC inhibitor) did not alter MARCKS distribution. Staurosporine 0-13 protein kinase C alpha Homo sapiens 65-68 9150270-5 1997 Staurosporine also increased membrane association of MARCKS in a PKC-independent manner, as no change in MARCKS phosphorylation was noted and bis-indolylmaleimide (a more specific PKC inhibitor) did not alter MARCKS distribution. Staurosporine 0-13 protein kinase C alpha Homo sapiens 180-183 9203625-9 1997 This finding is corroborated by the use of staurosporine, a nonselective PKC inhibitor, that prevented the effect of TPA. Staurosporine 43-56 protein kinase C alpha Homo sapiens 73-76 8626805-8 1996 Staurosporine inhibited the kinase activity of PKCalpha without affecting activation of PLD. Staurosporine 0-13 protein kinase C alpha Homo sapiens 47-55 7710931-11 1995 Staurosporine is not only a strong inhibitor of PKC but also mimics activators of this enzyme in that it elicits the cellular redistribution of certain PKC isoenzymes. Staurosporine 0-13 protein kinase C alpha Homo sapiens 48-51 7710931-11 1995 Staurosporine is not only a strong inhibitor of PKC but also mimics activators of this enzyme in that it elicits the cellular redistribution of certain PKC isoenzymes. Staurosporine 0-13 protein kinase C alpha Homo sapiens 152-155 7525931-5 1994 Staurosporine and calphostin C, which are two PKC inhibitors, inhibited EGF-induced enzyme activity and mRNA expression of 12-lipoxygenase. Staurosporine 0-13 protein kinase C alpha Homo sapiens 46-49 7923629-8 1994 To clarify the role of PKC in vasoconstrictor-stimulated VSMC production of bFGF and hypertrophy, PKC was down-regulated by prolonged exposure to PMA or was inhibited with calphostin C or staurosporine before the addition of TXA2 or Ang II. Staurosporine 188-201 protein kinase C alpha Homo sapiens 98-101 2185243-5 1990 Similarly, inhibition of PKC-epsilon by staurosporine and H-7 parallels inhibition of other PKC isotypes. Staurosporine 40-53 protein kinase C alpha Homo sapiens 25-28 7943245-10 1994 Furthermore, in these PKC-alpha downregulated cells staurosporine no longer increased the secosteroid-stimulated transient rise in [Ca2+]i. Staurosporine 52-65 protein kinase C alpha Homo sapiens 22-31 8224186-4 1993 All four cell lines continued to proliferate although at reduced rates in the presence of the PKC inhibitors staurosporine and H-7. Staurosporine 109-122 protein kinase C alpha Homo sapiens 94-97 8477816-5 1993 Pretreatment of mesangial cells with the PKC inhibitors staurosporine and K252a potently augmented inositol trisphosphate and 1,2-diacylglycerol formation as well as Ca2+ mobilization in response to angiotensin II. Staurosporine 56-69 protein kinase C alpha Homo sapiens 41-44 1444457-6 1992 Only the effect of the inhibitors on up-regulation of PKC-alpha was closely correlated with TPA-induced annexin I expression; staurosporine inhibited up-regulation of PKC-alpha but other inhibitors did not similarly affect the induction of annexin I expression. Staurosporine 126-139 protein kinase C alpha Homo sapiens 167-176 1577171-1 1992 In the human T-cell lymphoma line, HuT 78, proliferation and phorbol ester-induced growth arrest and differentiation were inhibited by the protein kinase C (PKC) inhibitor, staurosporine. Staurosporine 173-186 protein kinase C alpha Homo sapiens 157-160 1616823-5 1992 The hPKC alpha overexpressing cells had an altered, "transformed-like" morphology, which was reversed by staurosporine, an increased growth rate and a higher saturation density. Staurosporine 105-118 protein kinase C alpha Homo sapiens 4-14 8022414-10 1994 An analysis of the inhibition by UCN-01 and staurosporine of the kinase activity of PKC-alpha and -delta indicated mixed inhibition kinetics. Staurosporine 44-57 protein kinase C alpha Homo sapiens 84-93 1656952-2 1991 Inhibition of PKC by staurosporine and the selective PKC inhibitor CGP 41251 significantly reduced Epo formation. Staurosporine 21-34 protein kinase C alpha Homo sapiens 14-17 33986607-4 2021 Staurosporine (Stauro) was applied to activate GSK3 by inhibiting kinases that mediate inhibitory GSK3alpha/beta-Ser21/9 phosphorylation (eg, PKC). Staurosporine 0-13 protein kinase C alpha Homo sapiens 142-145 33986607-4 2021 Staurosporine (Stauro) was applied to activate GSK3 by inhibiting kinases that mediate inhibitory GSK3alpha/beta-Ser21/9 phosphorylation (eg, PKC). Staurosporine 0-6 protein kinase C alpha Homo sapiens 142-145 24682423-6 2014 This effect could be prevented using the PKC inhibitor staurosporine. Staurosporine 55-68 protein kinase C alpha Homo sapiens 41-44 32777211-9 2020 On the other hand, cell area, circularity or aspect ratio were affected by staurosporine in CXCL8 or CXCL10-activated cells, demonstrating a role of PKCalpha in the rearrangement of the cytoskeleton regardless of the effect on the migration. Staurosporine 75-88 protein kinase C alpha Homo sapiens 149-157 30776542-3 2019 To further reveal the mediated mechanism that Nrf2 active state was affected by protein kinase C (PKC), here we evaluated SVCV replication in host cells by treated with a strong activator of PKC phorbol-12-myristate-13-acetate (PMA) and an inhibitor staurosporine. Staurosporine 250-263 protein kinase C alpha Homo sapiens 98-101 30618318-0 2018 Low-dose staurosporine selectively reverses BCR-ABL-independent IM resistance through PKC-alpha-mediated G2/M phase arrest in chronic myeloid leukaemia. Staurosporine 9-22 protein kinase C alpha Homo sapiens 86-95 30618318-4 2018 Therefore, we herein used a PKC pan-inhibitor staurosporine (St). Staurosporine 46-59 protein kinase C alpha Homo sapiens 28-31 30618318-4 2018 Therefore, we herein used a PKC pan-inhibitor staurosporine (St). Staurosporine 61-63 protein kinase C alpha Homo sapiens 28-31 26398575-7 2015 The activation of NFAT by InB was largely suppressed by preincubation with protein kinase C (PKC) inhibitors such as staurosporine and K252a. Staurosporine 117-130 protein kinase C alpha Homo sapiens 93-96 19878671-5 2010 Angiotensin II induced inhibition of hOAT3 activity could be prevented by treating hOAT3-expressing cells with staurosporine, a general inhibitor for PKC, and with Go6976 (5,6,7,13-Tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile), a PKCalpha-specific inhibitor. Staurosporine 111-124 protein kinase C alpha Homo sapiens 150-153 19878671-5 2010 Angiotensin II induced inhibition of hOAT3 activity could be prevented by treating hOAT3-expressing cells with staurosporine, a general inhibitor for PKC, and with Go6976 (5,6,7,13-Tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile), a PKCalpha-specific inhibitor. Staurosporine 111-124 protein kinase C alpha Homo sapiens 271-279 19088254-6 2009 ANG II-induced inhibition of hOAT1 activity could be prevented by treating hOAT1-expressing cells with staurosporine, a general protein kinase C (PKC) inhibitor. Staurosporine 103-116 protein kinase C alpha Homo sapiens 146-149 19895572-5 2010 PMA-inhibition was reversed by PKC inhibitors recognising the ATP-binding site in PKC (e.g. staurosporin, GF109203X and Go6983). Staurosporine 92-104 protein kinase C alpha Homo sapiens 31-34 19895572-5 2010 PMA-inhibition was reversed by PKC inhibitors recognising the ATP-binding site in PKC (e.g. staurosporin, GF109203X and Go6983). Staurosporine 92-104 protein kinase C alpha Homo sapiens 82-85 19500428-3 2009 Here, we investigated the effect of staurosporine, a potent protein kinase C (PKC) inhibitor on the mobility and invasiveness of human lung adenocarcinoma A549 cells. Staurosporine 36-49 protein kinase C alpha Homo sapiens 78-81 19500428-7 2009 Western blot analyses were performed to study the effect of staurosporine on the levels of PKC-alpha, integrin beta1, E-cadherin, and LnR. Staurosporine 60-73 protein kinase C alpha Homo sapiens 91-100 19500428-16 2009 The staurosporine-mediated inhibition of PKC-alpha, induction of E-Cad expression, and decreased integrin beta1, LnR, MMP-9, and uPA levels could all possibly contribute to this biological process. Staurosporine 4-17 protein kinase C alpha Homo sapiens 41-50 17007817-7 2006 Staurosporine, a PKC inhibitor, and parthenolide, a NF-kappaB inhibitor, significantly reduced the CTT-dependent antiapoptotic effect. Staurosporine 0-13 protein kinase C alpha Homo sapiens 17-20 17013757-5 2006 Interestingly, the apoptotic events such as DNA ladders formation and activation of the caspase 3 cascade were significantly blocked by TPA addition in the presence of membrane translocation of PKCalpha, and TPA-induced protection was reduced by adding the PKC inhibitors, GF-109203X and staurosporin. Staurosporine 288-300 protein kinase C alpha Homo sapiens 194-202 17013757-5 2006 Interestingly, the apoptotic events such as DNA ladders formation and activation of the caspase 3 cascade were significantly blocked by TPA addition in the presence of membrane translocation of PKCalpha, and TPA-induced protection was reduced by adding the PKC inhibitors, GF-109203X and staurosporin. Staurosporine 288-300 protein kinase C alpha Homo sapiens 194-197